CORRELATION BETWEEN SERUM LEVELS OF HMGB1 AND A? WITH DISEASE SEVERITY IN PATIENTS WITH ACUTE ISCHEMIC STROKE

Objective: To explore the correlation between serum levels of HMGB1 and Ala and disease severity in patients with acute ischemic stroke (AIS). Methods: The data of 100 patients with AIS admitted to our hospital from February 2020 to February 2021 were selected for retrospective analysis. According to the National Institutes of Health Stroke Scale (NIHSS) score within 24 hours of admission, the patients were divided into the light group (LG), moderate group (MG) and severe group (SG), and 30 cases with health examination were the control group (CG). After taking the serum of patients, the levels of HMGB1 and Ala were measured to compare their differences among different groups and analyze the correlation between the levels of HMGB1 and Ala and the degree of neurological deficits. Results: The NIHSS score in the LG was overtly lower than the MG and SG (P<0.001), and the NIHSS score in the MG was visibly lower than the SG (P<0.001). The levels of HMGB1 and Ala in the LG were clearly lower than the MG and SG (P<0.001), and higher than the CG (P<0.001). The preliminary analysis of scatter diagram showed a trend of linear correlation between serum levels of HMGB1 and Ala and NIHSS, with no obvious outlier. According to r-analysis, the correlation between serum HMGB1 level and NIHSS showed r=0.930, r2=0.865, t=25.007 and Sig<0.001, and the correlation between Ala level and NIHSS showed r=0.970, r2=0.941, t=39.488 and Sig<0.001. Conclusion: The serum levels of HMGB1 and Ala in patients with AIS were positively correlated with the disease severity. In other words, the higher the serum levels of HMGB1 and Ala, the more severe the AIS.